Resources

Leading the way in defining a new Immunotherapy Response Score (IRS) to predict checkpoint inhibitor benefit

Clinical

Leading the way in defining a new Immunotherapy Response Score (IRS) to predict checkpoint inhibitor benefit

Early Phase Oncology Trial Designs Phase I Strategies Tailored for Success

Clinical

Early Phase Oncology Trial Designs Phase I Strategies Tailored for Success

CAR T-cell Program Development: Key Considerations

Blog

CAR T-cell Program Development: Key Considerations

TD2 Immuno-Oncology

Videos

TD2 Immuno-Oncology

Executive Interview with TD2

Videos

Executive Interview with TD2

TD2 Clinical Capabilities

Videos

TD2 Clinical Capabilities

Partner with an Experienced, Scientifically-Driven Cncology CRO

Videos

Partner with an Experienced, Scientifically-Driven Cncology CRO

Cell Therapy at TD2

Videos

Cell Therapy at TD2

CAR-T Summit Tech Slam

Videos

CAR-T Summit Tech Slam

Clinical Trial Highlight

Videos

Clinical Trial Highlight

Glioblastoma Capabilities

Videos

Glioblastoma Capabilities

Biomarkers and the utility of proteomics for dose optimization and confirmation of target engagement

Clinical

Biomarkers and the utility of proteomics for dose optimization and confirmation of target engagement

The Dynamic Trial Design

Preclinical

The Dynamic Trial Design

Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response

Preclinical

Checkpoint inhibitors: the gut microbiome’s role in anti-tumor response

Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers

Preclinical

Inhibition of HDAC3 Induces BRCAness and Potent Synergy with PARP Inhibition in Neuroendocrine Prostate and Small Cell Lung Cancers

Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…

Preclinical

Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…

Exploring the Effects of Microbiome in Precision Oncology Therapeutic Development

Preclinical

Exploring the Effects of Microbiome in Precision Oncology Therapeutic Development

Improving Cancer Trial Recruitment With Advanced Analytics and Prospective Data

Clinical

Improving Cancer Trial Recruitment With Advanced Analytics and Prospective Data

Data Insights: Identifying Early Signs of Safety and Efficacy in Oncology Clinical Trials

Clinical

Data Insights: Identifying Early Signs of Safety and Efficacy in Oncology Clinical Trials

The Dynamic Trial: Is It the Right Option for You?

Clinical

The Dynamic Trial: Is It the Right Option for You?

Efficient Data Management: One Way to Expedite the Clinical Development Process

Clinical

Efficient Data Management: One Way to Expedite the Clinical Development Process

Many Drugs Don’t Move Past Phase I. Will Yours?

Preclinical

Many Drugs Don’t Move Past Phase I. Will Yours?

Preclinical

CAR T-Cell Therapy: Revolutionizing Cancer Treatment

Clinical

The Quick-Start Guide to Clinical Strategy

Preclinical

6 Signs You Need a New CRO for Your Preclinical Research

PK/ADME

The A-Z Guide of DMPK Assays and How to Find the Right One

Clinical

The Trends Behind Successful Cancer Treatments

Clinical

Technology and Next-Generation Oncology Trials

STAY IN TOUCH

Get free tips, tools and resources by subscribing to the TD2 newsletter.

Sign Up Now
Skip to content